ABSTRACT
Background: hepatitis C Virus [HCV] has complex interactions with human lipid metabolism leading to down regulation of cholesterol level. Interferon [INF] therapy has been shown to decrease cholesterol even further during treatment .With the availability of direct acting antiviral agents [DAAs] the effect of suppressing HCV on lipid metabolism warrantes re-evaluation
Aim of the work : goal of our study was evaluation the changes in lipid profile after treatment of chronic HCV infection with oral antiviral medications in diabetic patients
Methods: this prospective study conducted on 90 HCV infected patients, all patients received Sofosbuvir [SOF] and Daclatasvir [DCV] as a dual therapy for 3 months. They were divided according to the presence or absence of diabetes mellitus [DM] and hyperlipidemia into three main groups; Group I: included 30 diabetic hyperlipidemic patients, Group II: included 30 non-diabetic hyperlipidemic patients, Group III: included 30 non-diabetic non- dyslipidemia patients.Changes of lipid profile on treatment with DAAs were assessed by checking fasting lipid profile at base line, then at end of treatment, and finally 3 months after treatment
Results: there was a statistically significant increase in total cholesterol level [TCHOL] which was maintained after the end of therapy. Changes in TCHOL were driven by changes in low-density lipo-protein [LDL] cholesterol, whereas high-density lipo-protien [HDL] cholesterol and very low-density lipo-protein [VLDL] cholesterol showed no significant changes. There were also no significant changes in tryglyceride [TG] level on treatment
Conclusion: eliminating HCV with DAAs increased TCHOL but had no effect on TG level